Payment overview · 2025
General Payments
$5,006.63
256 reported records · 29 companies
Healthcare provider profile · identity verified
Matthew C Haley, DO
Allopathic & Osteopathic Physicians|Family Medicine · CARBONDALE, PA · NPI 1851384085
Verified facts
What the public records show
CMS Open Payments records show Matthew C Haley, DO received $5,006.63 in general payments during 2025 across 256 reported records.
Boston Scientific Corporation accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Entresto, Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Qulipta, Rexulti, Trelegy Ellipta, Trintellix, Wegovy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 822 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 943 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 338 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 943 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xifaxan by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $663.19 | 13.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $551.33 | 11.0% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $429.78 | 8.6% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $416.43 | 8.3% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $389.31 | 7.8% | 29 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $348.62 | 7.0% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $318.84 | 6.4% | 19 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $219.78 | 4.4% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $209.17 | 4.2% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $201.31 | 4.0% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $180.08 | 3.6% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $164.52 | 3.3% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $160.98 | 3.2% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $102.19 | 2.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.79 | 2.0% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $101.57 | 2.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.55 | 1.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.62 | 1.3% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.25 | 1.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.27 | 1.0% | 7 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $37.18 | 0.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.23 | 0.6% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.20 | 0.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.50 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.89 | 0.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.51 | 0.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.11 | 0.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.10 | 0.4% | 1 | 2025 |
| Prescient Lab Services, LLC | Unresolved — no canonical attribution shown | $14.33 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,006.63 | 256 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $416.43 | 22 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $332.44 | 22 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $325.50 | 17 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $282.37 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $275.06 | 15 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $253.05 | 4 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $237.87 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $234.49 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $231.66 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $231.29 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $231.15 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $229.31 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $229.31 | 18 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $219.78 | 11 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $209.17 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $185.99 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $180.08 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $160.00 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $159.06 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.48 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $148.05 | 9 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $124.30 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $116.64 | 9 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $102.19 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.55 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.42 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $67.68 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.62 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $65.71 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.07 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.86 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $56.86 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.27 | 7 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $47.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.78 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.23 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| AVERTD AMPLIFICATION MIX Normalized: avertd amplification mix |
Device | Prescient Lab Services, LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AVERTD BIOFILMCHIP MICROARRAY MAGAZINE Normalized: avertd biofilmchip microarray magazine |
Device | Prescient Lab Services, LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AVERTD INTELLIPAC REAGENT MODULE Normalized: avertd intellipac reagent module |
Device | Prescient Lab Services, LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| PreScript Normalized: prescript |
Device | Prescient Lab Services, LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 943 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 144 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 822 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 338 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 128 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
822 | 100 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
943 | 98 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
128 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
144 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
338 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
943 | 98 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1479 | 244 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1419 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1311 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 1263 | 204 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1038 | 214 |
| Furosemide | Furosemide | 997 | 136 |
| Eliquis | Apixaban | 943 | 98 |
| Farxiga | Dapagliflozin Propanediol | 822 | 100 |
| Metformin Hcl | Metformin Hcl | 774 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 768 | 124 |
| Omeprazole | Omeprazole | 682 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 620 | 100 |
| Gabapentin | Gabapentin | 581 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 511 | 69 |
| Losartan Potassium | Losartan Potassium | 507 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 500 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 484 | 54 |
| Lisinopril | Lisinopril | 482 | 91 |
| Famotidine | Famotidine | 476 | 57 |
| Donepezil Hcl | Donepezil Hcl | 467 | 37 |
| Potassium Chloride | Potassium Chloride | 457 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 450 | 106 |
| Carvedilol | Carvedilol | 384 | 78 |
| Trazodone Hcl | Trazodone Hcl | 378 | 54 |
| Simvastatin | Simvastatin | 367 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 350 | 41 |
| Clonazepam | Clonazepam | 339 | 37 |
| Ozempic | Semaglutide | 338 | 62 |
| Mirtazapine | Mirtazapine | 337 | 35 |
| Allopurinol | Allopurinol | 317 | 57 |
| Sertraline Hcl | Sertraline Hcl | 294 | 36 |
| Ezetimibe | Ezetimibe | 280 | 46 |
| Myrbetriq | Mirabegron | 275 | 25 |
| Methylprednisolone | Methylprednisolone | 273 | 209 |
| Lorazepam | Lorazepam | 254 | 47 |
| Memantine Hcl | Memantine Hcl | 247 | 15 |
| Meloxicam | Meloxicam | 245 | 53 |
| Montelukast Sodium | Montelukast Sodium | 236 | 44 |
| Alprazolam | Alprazolam | 224 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 220 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 73 |
| Risperidone | Risperidone | 219 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 57 |
| Aripiprazole | Aripiprazole | 198 | 11 |
| Sucralfate | Sucralfate | 194 | 13 |
| Prednisone | Prednisone | 188 | 72 |
| Pioglitazone Hcl | Pioglitazone Hcl | 186 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 53 |
| Buspirone Hcl | Buspirone Hcl | 179 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 172 | 51 |
| Baclofen | Baclofen | 170 | 34 |
| Tramadol Hcl | Tramadol Hcl | 169 | 35 |
| Olanzapine | Olanzapine | 161 | suppressed |
| Mounjaro | Tirzepatide | 153 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 27 |
| Finasteride | Finasteride | 148 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 19 |
| Levetiracetam | Levetiracetam | 145 | 20 |
| Entresto | Sacubitril/Valsartan | 144 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 21 |
| Benazepril Hcl | Benazepril Hcl | 135 | 26 |
| Clonidine Hcl | Clonidine Hcl | 135 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 135 | 45 |
| Lamotrigine | Lamotrigine | 135 | suppressed |
| Torsemide | Torsemide | 134 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 26 |
| Warfarin Sodium | Warfarin Sodium | 128 | 19 |
| Divalproex Sodium | Divalproex Sodium | 126 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 20 |
| Jardiance | Empagliflozin | 123 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 122 | 16 |
| Spironolactone | Spironolactone | 121 | 35 |
| Januvia | Sitagliptin Phosphate | 118 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 14 |
| Movantik | Naloxegol Oxalate | 117 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 117 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 114 | 13 |
| Pregabalin | Pregabalin | 112 | 18 |
| Alendronate Sodium | Alendronate Sodium | 110 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 105 | 12 |
| Celecoxib | Celecoxib | 101 | 22 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 101 | 15 |
| Memantine Hcl Er | Memantine Hcl | 95 | suppressed |
| Valsartan | Valsartan | 95 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 17 |
| Ibuprofen | Ibuprofen | 91 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 18 |
| Dutasteride | Dutasteride | 85 | 11 |
| Xarelto | Rivaroxaban | 85 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 13 |
| Propranolol Hcl | Propranolol Hcl | 75 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 72 | 15 |
| Midodrine Hcl | Midodrine Hcl | 72 | suppressed |
| Linzess | Linaclotide | 71 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 27 |
| Labetalol Hcl | Labetalol Hcl | 70 | 16 |
| Terazosin Hcl | Terazosin Hcl | 70 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 67 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | suppressed |
| Atenolol | Atenolol | 66 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 65 | 17 |
| Irbesartan | Irbesartan | 64 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 64 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 63 | suppressed |
| Repatha Sureclick | Evolocumab | 61 | 11 |
| Naproxen | Naproxen | 59 | suppressed |
| Novolog Flexpen | Insulin Aspart | 59 | 14 |
| Calcitriol | Calcitriol | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 12 |
| Ramipril | Ramipril | 54 | suppressed |
| Amantadine | Amantadine Hcl | 53 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 53 | suppressed |
| Lactulose | Lactulose | 52 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 15 |
| Latanoprost | Latanoprost | 48 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 48 | 16 |
| Meclizine Hcl | Meclizine Hcl | 47 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | 11 |
| Nateglinide | Nateglinide | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 16 |
| Chlorthalidone | Chlorthalidone | 44 | suppressed |
| Kerendia | Finerenone | 44 | suppressed |
| Budesonide | Budesonide | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Xifaxan | Rifaximin | 43 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Oxycontin | Oxycodone Hcl | 41 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Cefdinir | Cefdinir | 36 | 30 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 36 | 36 |
| Repatha Syringe | Evolocumab | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Cilostazol | Cilostazol | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 16 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Nabumetone | Nabumetone | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Lacosamide | Lacosamide | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 13 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Buprenorphine | Buprenorphine | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 13 |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Enulose | Lactulose | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Primidone | Primidone | 22 | suppressed |
| Wegovy | Semaglutide | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 20 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Savella | Milnacipran Hcl | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Paliperidone Er | Paliperidone | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 19 | suppressed |
| Travoprost | Travoprost | 19 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 15 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Oxazepam | Oxazepam | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Admelog Solostar | Insulin Lispro | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Gemtesa | Vibegron | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Mupirocin | Mupirocin Calcium | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,006.63 · 256 records | Boston Scientific Corporation | AIRSUPRA, AVERTD AMPLIFICATION MIX, AVERTD BIOFILMCHIP MICROARRAY MAGAZINE, AVERTD INTELLIPAC REAGENT MODULE, Auvelity, BREZTRI, BRIXADI, CAMZYOS, CAPLYTA, CAPVAXIVE, CREON, Dexcom G6 Transmitter, ELIQUIS, EMBLEM MRI S-ICD, ENTRESTO, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, General - Brady, General - Tachy, INGREZZA, Kerendia, LEQVIO, LINZESS, LUX-Dx Insertable Cardiac Monitor, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, PreScript, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error